No abstract

No abstract

Prospective, randomized, double-blinded clinical trial, Level I.

Purpose Interscalene brachial plexus block (ISB) is one of the most commonly used regional blocks in relieving postoperative pain after arthroscopic rotator cuff repair. Dexmedetomidine (DEX) is an alpha 2 agonist that can enhance the effect of regional blocks. The aim of this study was to compare the effects of DEX combined with ISB with ISB alone on postoperative pain, satisfaction, and pain‐related cytokines within the first 48 h after arthroscopic rotator cuff repair. Methods Fifty patients with rotator cuff tears who had undergone arthroscopic rotator cuff repair were enrolled in this single center, double‐blinded randomized controlled trial study. Twenty‐five patients were randomly allocated to group 1 and received ultrasound‐guided ISB using a mixture of 1 ml (100 μg) of DEX and 8 ml of 0.75% ropivacaine preemptively. The other 25 patients were allocated to group 2 and underwent ultrasound‐guided ISB alone using a mixture of 1 ml of normal saline and 8 ml of ropivacaine. The visual analog scale (VAS) for pain and patient satisfaction (SAT) scores were checked within 48 h postoperatively. The plasma interleukin (IL)‐6, ‐8, ‐1β, cortisol, and substance P levels were also measured within 48 h, postoperatively. Results Group 1 showed a significantly lower mean VAS score and a significantly higher mean SAT score than group 2 at 1, 3, 6, 12, and 18 h postoperatively. Compared with group 2, group 1 showed a significantly lower mean plasma IL‐6 level at 1, 6, 12, and 48 h postoperatively and a significantly lower mean IL‐8 level at 1, 6, 12, 24, and 48 h postoperatively. The mean timing of rebound pain in group 1 was significantly later than that in group 2 (12.7 h > 9.4 h, p = 0.006). Conclusions Ultrasound‐guided ISB with DEX in arthroscopic rotator cuff repair led to a significantly lower mean VAS score and a significantly higher mean SAT score within 48 h postoperatively than ISB alone. In addition, ISB with DEX showed lower mean plasma IL‐6 and IL‐8 levels than ISB alone within 48 h postoperatively, with delayed rebound pain. Level of evidence I. Trial Registration 2013‐112, ClinicalTrials.gov Identifier: NCT02766556.